Compare Gilead Sciences, Inc. (GILD) vs Rush Street Interactive Inc (RSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Rush Street Interactive Inc — how do they compare? Gilead Sciences, Inc. trades at $133.72 (market cap $163.51B), while Rush Street Interactive Inc trades at $32.8 (market cap $3.39B). The key difference: Gilead Sciences, Inc. is far larger — about 48.2× Rush Street Interactive Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Rush Street Interactive Inc pays none. Which is the better fit depends on your goals.
| GILD | RSI | |
|---|---|---|
Market Cap | $163.51B | $3.39B |
Sector | Health | Technology |
52-Week High | $155.80 | $34.18 |
52-Week Low | $108.22 | $14.51 |
Enterprise Value | $178.05B | $3.07B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Rush Street Interactive (RSI) trades at $33.57, up 0.18% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating EPS estimates with $0.14 actual versus $0.12 expected, and revenue growth to $1.13 billion in 2025. Analyst sentiment is positive with 10 buy ratings and a consensus price target of $30.44. Recent expansion into Alberta through BetRivers highlights ongoing growth initiatives.
The outlook for RSI is favorable due to robust revenue growth and strategic market expansions, though high valuation multiples like a P/E of 96.85 pose risks. Key opportunities include continued online betting demand, while risks involve competitive pressures and execution of growth strategies. The stock's momentum is supported by institutional confidence but requires monitoring of profit margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →
